Disgraced biotech executive Martin Shkreli has shifted into full attack mode, simultaneously taking on the U.S. Congress and Ghostface Killah. Which antagonist poses more of a threat is open to debate.
A brief recap: Shkreli, 32, ran hedge funds and a pair of biotech drug manufacturers before gaining extreme notoriety last year for raising the price of a lifesaving AIDS drug by more than 5,000 percent. Then he got indicted for securities fraud. Most recently, Shkreli requested that a federal judge in New York intervene to help him avoid being charged with criminal contempt if he doesn't appear before a congressional committee. His appearance, initially scheduled for Tuesday, was postponed after a weekend blizzard inundated the nation's capital.